Aclaris Therapeutics

ACRS

Market cap $348M

3.21 USD

+0.04

1.26%

At close Updated Dec 16, 4:00 PM EST

Pre-market

After hours

3.23

+0.02

0.62%

1 day

1.26%

5 days

1 month

31.02%

3 months

74.46%

6 months

122.92%

Year to date

29.44%

1 year

6.29%

5 years

-35.93%

10 years

-87.64%

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Employees: 64

Healthcare Biotechnology